11. Claim 1: peptide, including the amino acid sequence selected from groups SEQ 1 to SEQ No. 385, and at least 88% of the alternative sequences matched with one or more molecules in groups SEQ 1 to SEQ No. 3, and combined with one or more molecules in the larger synthetic body. Histocompatibility (MHC) and / or induced T-lymphocytes to cross react with the variability of this peptide； and a pharmaceutically acceptable salt, where this peptide is not a complete peptide. Claim 12: a test tube method for producing activated T lymphocytes,2.1.2.1.1.2. The method includes contacting the T-lymphocytes in the test tube containing class I or class II human MHC molecules with the antigen display cells displayed on the surface of the appropriate antigen display cells or in the artificial structure, and simulating them into antigen display cells for a long time This T-cell is a specific antigen, and this antigen is a peptide that meets any requirements of 1-4. Claim 16: the peptide is used according to any requirements of items 1 to 6, and the nucleic acid is used according to the requirements of item 7,(a) Expression vector meeting the requirements of item 8； cell meeting the requirements of Item 9； active T-lymphocyte meeting the requirements of item 13； or antibody meeting the requirements of item 15 for diagnosis and / or treatment of cancer or production of cancer drugs. Requirement 21: production of personalized cancer vaccines for individual patients or methods of treatment with compounds and / or cells, including: (a) identification of tumor related peptides in tumor samples of relevant patients；(b) Compare (a) the identified peptide with a pre screened peptide profile based on its immunity and / or overweight in tumor relative to normal tissue； (c) select at least one peptide from the profile that is consistent with the drug resistance determined by the patient； (d) Manufacturing and / or developing custom vaccines or treatment based on compounds or cells based on st
